March 5, 2026 Starton Therapeutics Files Patent Applications for the Use of CAR-T Therapies in Combination with its Proprietary, Continuous Low-Dose Immunomodulatory Therapy, STAR-LLD, a formulation of Lenalidomide, for the Treatment of Blood Cancer
February 26, 2026 Starton Therapeutics Files Patent Application for the Use of Multi-Specific Antibody-Based Therapies in Combination with its Proprietary, Continuous Low-Dose Immunomodulatory Therapy, STAR-LLD, a formulation of Lenalidomide, for the Treatment of Blood Cancer
February 19, 2026 Starton Therapeutics Announces Dosing of First Patient in Phase 2a Study Evaluating STAR-LLD for the Treatment of Multiple Myeloma
October 8, 2025 Starton Therapeutics to Share Innovative Lenalidomide Delivery Technology on Labroots Webinar Sponsored by Primetech Corporation
October 2, 2025 Starton Therapeutics Announces Promotion of Rod Hartwig to Vice President of Research and Development and Manufacturing
October 1, 2025 Starton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO, October 27-28, 2025
September 16, 2025 Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD
June 24, 2025 Starton Therapeutics and Bend Bioscience Enter into Development Agreement for Oral Controlled Release Dosage Form of STAR-LLD (lenalidomide)
June 12, 2025 Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment
April 25, 2025 American Association for Cancer Research (AACR) Annual Meeting 2025 Poster Presentation: LB207: Continuous subcutaneous lenalidomide delivery improves the therapeutic index and avoids drug-related grade 3/4 hematologic toxicity in patients with relapsed/refractory multiple myeloma
April 25, 2025 Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025
